

Improving Data Collection Quality for Systemic Anti-Cancer Therapy (SACT) in Prostate Cancer

BACKGROUND

- Recent findings from the NPCA show a lower than expected percentage of men diagnosed with mHSPC receiving SACT treatment intensification

Under 75 years 75 years and older

66%

29%

Reported rates of men diagnosed with metastatic disease receiving SACT treatment intensification between Jan-Dec 2022 in England*

*NPCA State of the Nation Report 2025



NPCA

National Prostate Cancer Audit

AIMS:
To improve the completeness, accuracy, and timeliness of SACT data submission for men receiving SACT for prostate cancer within participating NHS organisations

OBJECTIVES



Increase the proportion of SACT record completeness



Reduce data submission errors



Strengthen collaborations between data management teams

INTERVENTION



✉ NPCA@rcseng.ac.uk
✕ @NPCA_uk

View the results of individual NHS Trusts and Cancer Alliances using our interactive Data Dashboard



CLINICAL RELEVANCE

- Among men in England diagnosed with hormone-sensitive metastatic prostate cancer (mHSPC) in 2022, only **47%** (2,670 of 5,679) received SACT treatment intensification within 12 months*

TIMELINE

